Treprostinil SC for PAH Change in 6-MWD (from Baseline to Week 12)
{"Image DocumentName": "Treprostinil SC for PAH Change in 6-MWD (from Baseline to Week 12)", "Image ImageDescription": "P = Change from Baseline (meters) N = 470. Covers learning objective 3) Use evidence-based guidelines to select the most appropriate treatment. Covers learning objective 5) Compare the side effect profiles and drug interaction potential of available PAH treatments to gauge the risk-benefit ratio of each option and to determine areas for patient monitoring. Simonneau and colleagues evaluated treprostinil subcutaneous in patients with PAH. Change in 6-MWD from baseline to week 12 was greatest for the highest dose of treprostinil < 5.0. ng/kg/min ng/kg/min. 8.2 \u2013 13.8 ng/kg/min. > 13.8 ng/kg/min. Simonneau, et al. Am J Respir Crit Care Med. 2002;165:800-4.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}